Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Conditions

• To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
• To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer
• Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer

Interventions

• DRUG: Pirfenidone
• DRUG: Fruquintinib
• DRUG: Pembrolizumab

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology